Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA - Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the biopharmaceutical company's stock.

Separately, HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Vanda Pharmaceuticals in a report on Monday, December 23rd.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ:VNDA traded down $0.05 on Friday, hitting $4.60. 555,117 shares of the company were exchanged, compared to its average volume of 523,103. The company's 50 day moving average price is $4.88 and its two-hundred day moving average price is $5.07. The firm has a market capitalization of $268.22 million, a price-to-earnings ratio of -16.43 and a beta of 0.77. Vanda Pharmaceuticals has a one year low of $3.46 and a one year high of $6.75.

Insider Buying and Selling

In other news, Director Stephen Ray Mitchell sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the sale, the director now owns 44,857 shares of the company's stock, valued at approximately $231,910.69. This trade represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 8.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of large investors have recently bought and sold shares of VNDA. Meeder Asset Management Inc. bought a new stake in shares of Vanda Pharmaceuticals during the second quarter valued at approximately $39,000. ORG Wealth Partners LLC bought a new position in Vanda Pharmaceuticals in the 3rd quarter valued at $40,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 4,374 shares during the period. XTX Topco Ltd bought a new stake in shares of Vanda Pharmaceuticals during the second quarter worth $75,000. Finally, Intech Investment Management LLC acquired a new position in shares of Vanda Pharmaceuticals during the third quarter valued at $84,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.